Foundation Medicine, Inc. (NASDAQ:FMI) CFO Jason Ryan sold 3,154 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $38.80, for a total transaction of $122,375.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jason Ryan also recently made the following trade(s):

  • On Thursday, July 13th, Jason Ryan sold 5,084 shares of Foundation Medicine stock. The stock was sold at an average price of $39.77, for a total transaction of $202,190.68.
  • On Thursday, July 6th, Jason Ryan sold 6,683 shares of Foundation Medicine stock. The stock was sold at an average price of $38.84, for a total transaction of $259,567.72.

Shares of Foundation Medicine, Inc. (FMI) traded up 7.108% on Thursday, hitting $44.075. 235,929 shares of the company traded hands. The stock’s 50-day moving average price is $39.26 and its 200-day moving average price is $37.30. The company’s market capitalization is $1.59 billion. Foundation Medicine, Inc. has a 12 month low of $17.10 and a 12 month high of $44.95.

Foundation Medicine (NASDAQ:FMI) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.08) by ($0.16). Foundation Medicine had a negative net margin of 131.79% and a negative return on equity of 109.63%. The business had revenue of $35.00 million during the quarter, compared to analysts’ expectations of $34.94 million. During the same quarter last year, the company earned ($0.84) EPS. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year. On average, equities analysts predict that Foundation Medicine, Inc. will post ($4.67) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/foundation-medicine-inc-fmi-cfo-jason-ryan-sells-3154-shares.html.

Hedge funds have recently added to or reduced their stakes in the stock. Fiduciary Trust Co. purchased a new stake in Foundation Medicine in the 2nd quarter valued at $119,000. Legal & General Group Plc raised its position in Foundation Medicine by 8.6% in the 2nd quarter. Legal & General Group Plc now owns 3,442 shares of the company’s stock valued at $138,000 after purchasing an additional 274 shares during the last quarter. Bank of America Corp DE raised its position in Foundation Medicine by 65.8% in the 1st quarter. Bank of America Corp DE now owns 6,180 shares of the company’s stock valued at $200,000 after purchasing an additional 2,452 shares during the last quarter. Creative Planning raised its position in Foundation Medicine by 15.3% in the 2nd quarter. Creative Planning now owns 5,075 shares of the company’s stock valued at $202,000 after purchasing an additional 675 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System purchased a new stake in Foundation Medicine in the 1st quarter valued at $218,000. Hedge funds and other institutional investors own 31.84% of the company’s stock.

FMI has been the subject of a number of research analyst reports. BidaskClub cut shares of Foundation Medicine from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 17th. Zacks Investment Research cut shares of Foundation Medicine from a “hold” rating to a “sell” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $35.00.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Stock Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related stocks with our FREE daily email newsletter.